Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Ligand Pharmaceuticals Incorporated(LGND)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LGND
11/13/2026: LGND (3-star) is a STRONG-BUY. BUY for 35 days. Simulated Profits (-1.69%). Updated daily EoD!
Ligand Pharmaceuticals is a biotechnology company that has transitioned into a focused business model centered on royalty streams and the Captisol drug delivery platform. By acquiring economic interests in drug development, it captures value from the commercial success of partner-led therapies while minimizing internal R&D overhead. The company has a leading position in proprietary solubility technologies, which provides a steady, high-margin revenue base. Risks include its dependency on external partners for clinical and commercial success and the potential for increased competition in the royalty space. Ligand may suit growth-oriented investors looking for exposure to biotech innovation without the direct risks of pure-play drug discovery.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Ligand offers growth potential through royalty portfolio expansion, though it lacks the explosive growth typical of early-stage, high-R&D biotech. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of positive news flow regarding partner drug approvals and milestone payments. |
| Value investor | Mixed fit | Valuation depends on the long-term cash flow projections of the royalty portfolio, which can be complex to value precisely. |
| Dividend investor | Weak fit | The company does not pay a regular dividend, prioritizing capital reinvestment. |
| Low-risk investor | Weak fit | Biotech exposure inherently carries clinical and regulatory risks that lead to significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are sensitive to clinical trial outcomes and partner commercial performance. |
| Valuation risk | Medium | Future cash flows depend on the market success of partner drugs, creating uncertainty in long-term valuations. |
| Competition risk (Royalty aggregation) | Medium / high | Increased capital in the royalty space from firms like RPRX makes securing new deals more expensive. |
| Business quality | Medium | The business relies heavily on external partners to commercialize drugs successfully. |
| Dividend income | Low / none | No current dividend policy makes it unsuitable for income-focused portfolios. |
| Execution risk | Medium | Success is largely dependent on the execution capabilities of external partners. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.33B USD | Price to earnings Ratio 127.02 | 1Y Target Price 361.27 |
Price to earnings Ratio 127.02 | 1Y Target Price 361.27 | ||
Volume (30-day avg) 217.2K shares | Beta 1.03 | 52 Weeks Range 175.89 - 326.63 | Updated Date 11/13/2026 |
52 Weeks Range 175.89 - 326.63 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.49 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 68.2% | Avg. Invested days 41 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Royalties | Revenue from contractual royalty percentages on net sales of licensed partner drugs. | This is the core business; you get paid when partners successfully sell their medicines. |
| Captisol Licensing | Fees from licensing the Captisol drug delivery platform to pharmaceutical companies. | This provides a steady revenue stream by helping other companies solve drug solubility issues. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 1.42 | Actual -1.43 |
Profitability
Profit Margin 20.27% | Operating Margin (TTM) 14.38% |
Management Effectiveness
Return on Assets (TTM) 1.23% | Return on Equity (TTM) 5.38% |
Valuation
Trailing PE 127.02 | Forward PE 25.64 | Enterprise Value 7.01B | Price to Sales(TTM) 24.92 |
Enterprise Value 7.01B | Price to Sales(TTM) 24.92 | ||
Enterprise Value to Revenue 27.64 | Enterprise Value to EBITDA 73.18 | Shares Outstanding 20.00M | Shares Floating 19.55M |
Shares Outstanding 20.00M | Shares Floating 19.55M | ||
Percent Insiders 2.3 | Percent Institutions 117.71 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.